Concerns Over Valeant Spread to Other Drug Makers

As questions mount about the viability of Valeant Pharmaceuticals International Inc.’s business model, writes the Wall Street Journal, concerns are spreading to other drug makers seen as following a similar playbook. Like Valeant, these firms are part of a new breed of pharmaceutical company that has limited costly investment in research and development and instead sought sales growth through debt-fueled acquisitions—often of older drugs for which they raise prices sharply.

Leave a Reply

Fill in your details below or click an icon to log in:

WordPress.com Logo

You are commenting using your WordPress.com account. Log Out /  Change )

Google photo

You are commenting using your Google account. Log Out /  Change )

Twitter picture

You are commenting using your Twitter account. Log Out /  Change )

Facebook photo

You are commenting using your Facebook account. Log Out /  Change )

Connecting to %s